Huvepharma vaccine expands coccidiosis toolkit for broiler-breeders and commercial layer producers

The USDA Center for Veterinary Biologics has granted Huvepharma approval for the manufacturing and sale of a new broiler-breeder coccidiosis vaccine, Advent^® P, which contains Eimeria necatrix and E. brunetti.

“This vaccine was specifically designed to address issues faced by broiler-breeders and commercial layer producers, closing a gap in coccidiosis coverage for our customers,” said David Smith, DVM, Huvepharma’s Director of Poultry Technical Services.

Coccidiosis is a prolific and costly intestinal disease that can be found in all production animal species. In the broiler-breeder industry, coccidiosis negatively impacts multiple facets, including production efficiency, therapeutic costs and bird mortality. Advent P represents an additional coccidiosis solution for the poultry industry.

“Completing the Advent portfolio with Advent P is an exciting advancement for our poultry team and the entirety of Huvepharma,” said Daniel Lackey, Director of Product Management and Marketing with Huvepharma.

Advent P will be available for purchase within the coming months. The vaccine has a shelf life of 9 months and will be packaged in 10 x 10,000-dose clamshells. It can be applied by spray cabinet at day of age or on feed.

For more information, please visit www.huvepharma.us.

The post Huvepharma vaccine expands coccidiosis toolkit for broiler-breeders and commercial layer producers appeared first on Modern Poultry.